- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Cutting Edge Biotech Companies Human Genome Sciences (HGSI) and Dendreon Corp. (DNDN) Are Poised To Go Higher
Recent Articles by Benzinga Staff
- Biotech Stock Mailbag: Generex (PFE, MNKD)
- Apple Is Hoping To Have Apps For That (AAPL)
- Potential Reversals 3/19/10
- Coal Prices Ready To Burn Hot In 2010?
- Stifel Nicolaus Still Gives TriQuint A Buy (TQNT)
Long Ideas
- Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, VITC, PTV, IP, STXS, ABT, NMM, ATPG, GMCR)
- Fast Money Picks For March 22nd (MHS, CVS)
- Cramer Recommends Sonus Networks As A Speculative Play (SONS)
- Biotech Stock Mailbag: Generex (PFE, MNKD)
- Apple Is Hoping To Have Apps For That (AAPL)
FDA
- FDA Approves Medtronic (MDT) Diabetes Management System
- Boston Scientific Corporation (BSX) Options Active On Positive FDA Data
- Boston Scientific Corp. Halts Sale Of ICDs (BSX)
- Amylin Shooting Higher
- Medtronic (MDT) Gets FDA Approval For Epilepsy Treatment
Trading Ideas
Posted on 11/05/09 at 1:00pm by Benzinga Staff
Planning to invest in the biotech sector? Louis Navallier says to look for companies like Human Genome Sciences (NASDAQ: HGSI) and Dendreon Corp. (NASDAQ: DNDN) that are on the cutting-edge of innovation, research and developing treatments for major diseases.
After HGSI's drug for Lupus, Benlysta, showed good results in a late stage clinical trial, its stock prices went up. The company partnered with pharmaceutical giant GlaxoSmithKline (NYSE: GSK) to cover the testing expenses. Human Genome's drug for Lupus - a painful disease that occurs when the body's immune system attacks its own healthy tissues - has not been approved in 50 years, and this kind of medication has tremendous revenue potential. Its shares upgraded by almost 50% recently, and Louis Navallier suggests you buy it before it gets any higher, which it very probably will.
Dendreon Corp., whose main product is Provenge, a vaccine for the treatment of prostate cancer, is another important up and coming biotech firm. Dendreon just submitted its drug to the FDA for approval, and it is approved, it will be the only drug of its kind that is available in the US. You can imagine the revenue potential.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
There are 3 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
UMM...lol you need 2 check
by RJFSMoney on 11/05/09 1:15pm
UMM...lol you need 2 check your grammer in that last section about Dendreon
DYAX fda action date set Dec
by Anonymous on 11/05/09 2:25pm
DYAX fda action date set Dec 1st for approval of DX-88 for the treatment of HAE. If approved Dyax wil have the only treatment marketed in the US to treat the potentially fatal Hereditary Angio Edema. DX-88 has also shown to be beneficial for other treatments as well and is being evaluated accordingly
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
